Production (Stage)
Achieve Life Sciences, Inc.
ACHV
$3.04
$0.072.36%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 82.12% | 115.40% | 62.39% | 6.04% | 4.57% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.55% | 177.93% | 89.68% | 9.29% | -30.26% |
| Operating Income | -115.55% | -177.93% | -89.68% | -9.29% | 30.26% |
| Income Before Tax | -97.52% | -125.71% | -76.03% | -2.69% | 27.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -97.52% | -125.71% | -76.03% | -2.69% | 27.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -97.52% | -125.71% | -76.03% | -2.69% | 27.78% |
| EBIT | -115.55% | -177.93% | -89.68% | -9.29% | 30.26% |
| EBITDA | -116.57% | -180.25% | -90.50% | -9.34% | 30.46% |
| EPS Basic | -42.61% | -38.42% | -8.26% | 43.01% | 48.33% |
| Normalized Basic EPS | -42.81% | -47.64% | -5.23% | 43.36% | 48.77% |
| EPS Diluted | -42.61% | -38.42% | -8.26% | 43.01% | 48.33% |
| Normalized Diluted EPS | -42.81% | -47.64% | -5.23% | 43.36% | 48.77% |
| Average Basic Shares Outstanding | 38.47% | 63.05% | 62.61% | 80.16% | 39.79% |
| Average Diluted Shares Outstanding | 38.47% | 63.05% | 62.61% | 80.16% | 39.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |